Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-1.91% $1.403
America/New_York / 19 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 48.45 mill |
EPS: | -0.610 |
P/E: | -2.30 |
Earnings Date: | Dec 27, 2023 |
SharesOutstanding: | 34.54 mill |
Avg Daily Volume: | 0.167 mill |
RATING 2024-04-19 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Neutral | |
Return On Asset: | Buy | |
DE: | Neutral | |
P/E: | Buy | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/21 | 3/21 | 1/22 | 3/22 | 1/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
Ebit | n/a | n/a | n/a | n/a | n/a | |
Asset | ||||||
Debt | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.30 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.39x |
Company: PE -2.30 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.102 (-92.72%) $-1.301 |
Date: 2024-04-20 |
Expected Trading Range (DAY) |
---|
$ 1.264 - 1.536 ( +/- 9.71%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-27 | Cerrone Gabriele M | Buy | 70 071 | Ordinary Shares |
2023-10-23 | Cerrone Gabriele M | Buy | 499 468 | Ordinary Shares |
2023-09-15 | Brancaccio John P | Buy | 16 670 | Ordinary Shares |
2022-05-19 | Cerrone Gabriele M | Buy | 5 800 000 | Ordinary Shares |
2022-05-19 | Jacob Gary S | Buy | 12 500 | American Depositary Shares |
INSIDER POWER |
---|
-58.39 |
Last 18 transactions |
Buy: 8 086 209 | Sell: 58 400 000 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.403 (-1.91% ) |
Volume | 0.0132 mill |
Avg. Vol. | 0.167 mill |
% of Avg. Vol | 7.95 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.